drugset / Trial / NCT00649896

Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day

NCT00649896

Phase 1 Completed 76 enrolled Mylan Pharmaceuticals Inc
RandomizedSingle-groupSingle-blind

Summary

The primary objective of this study was to compare the adhesive quality of a new formulation of the Mylan Estradiol Transdermal System with that of Climara® Transdermal System following a single system application in 80 healthy postmenopausal female volunteers. As a secondary objective, primary dermal irritation was assessed after removal of each transdermal system.

Timeline

Start
2003-08
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Estradiol Other / unclassified 0.025 mg Other

Indications

No indication recorded.